paclitaxel has been researched along with Central Nervous System Neoplasm in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (27.27) | 18.2507 |
| 2000's | 5 (45.45) | 29.6817 |
| 2010's | 3 (27.27) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Amiri-Kordestani, L; Liewehr, DJ; Lin, NU; Palmieri, D; Steeg, PS | 1 |
| Awada, A; Bachelot, T; Badwe, RA; Bondarenko, I; Bose, R; Bryce, R; Carey, LA; Colomer, R; Demetriou, G; Deo, S; Goswami, C; Inoue, K; Kim, SB; Lee, SC; Mehta, AO; Wong, A; Xu, F; Yao, B | 1 |
| Hide, M; Hori, I; Kamegashira, A; Madokoro, N; Mihara, S; Noda, H; Shindo, H; Takahagi, S | 1 |
| Anelli, V; Bassi, R; Brioschi, L; Campanella, R; Caroli, M; De Zen, F; Gaini, SM; Giussani, P; Riboni, L; Riccitelli, E; Viani, P | 1 |
| Abali, H; Celik, I | 1 |
| Brem, H; Dang, W; Li, KW; Tihan, T; Troiano, G; Tyler, BM; Walter, KA | 1 |
| Burstein, HJ; Klein, P; Lieberman, G; Slamon, DJ; Winer, EP | 1 |
| Banik, NL; Karmakar, S; Ray, SK | 1 |
| Brown, WS; Cain, JM; Figge, DC; Greer, BE; Seewaldt, VL; Tamimi, HK | 1 |
| DeAngelis, LM; Freilich, RJ; Seidman, AD | 1 |
| Holm, B; Jensen, PB; Sehested, M | 1 |
1 review(s) available for paclitaxel and Central Nervous System Neoplasm
| Article | Year |
|---|---|
CNS metastases in breast cancer: old challenge, new frontiers.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Central Nervous System Neoplasms; Clinical Trials as Topic; Female; Humans; Neoplasm Recurrence, Local; Paclitaxel; Radionuclide Imaging; Radiopharmaceuticals; Trastuzumab | 2013 |
3 trial(s) available for paclitaxel and Central Nervous System Neoplasm
| Article | Year |
|---|---|
Neratinib Plus Paclitaxel vs Trastuzumab Plus Paclitaxel in Previously Untreated Metastatic ERBB2-Positive Breast Cancer: The NEfERT-T Randomized Clinical Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Central Nervous System Neoplasms; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Paclitaxel; Quinolines; Receptor, ErbB-2; Trastuzumab | 2016 |
Isolated central nervous system metastases in patients with HER2-overexpressing advanced breast cancer treated with first-line trastuzumab-based therapy.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Central Nervous System Neoplasms; Cyclophosphamide; Disease Progression; Doxorubicin; Female; Follow-Up Studies; Gene Amplification; Humans; In Situ Hybridization, Fluorescence; Paclitaxel; Prevalence; Receptor, ErbB-2; Survival Rate; Time Factors; Trastuzumab; Vinblastine; Vinorelbine | 2005 |
Central nervous system progression of metastatic breast cancer in patients treated with paclitaxel.
Topics: Blood-Brain Barrier; Brain Neoplasms; Breast Neoplasms; Central Nervous System Neoplasms; Female; Humans; Neoplasm Metastasis; Paclitaxel | 1995 |
7 other study(ies) available for paclitaxel and Central Nervous System Neoplasm
| Article | Year |
|---|---|
Metastatic extramammary Paget's disease treated with paclitaxel and trastuzumab combination chemotherapy.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Central Nervous System Neoplasms; Genital Neoplasms, Male; Humans; Male; Paclitaxel; Paget Disease, Extramammary; Skin; Skin Neoplasms; Trastuzumab | 2009 |
Glucosylceramide synthase protects glioblastoma cells against autophagic and apoptotic death induced by temozolomide and Paclitaxel.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Apoptosis; Autophagy; Cell Line, Tumor; Cell Proliferation; Cell Survival; Central Nervous System Neoplasms; Ceramides; Dacarbazine; Drug Resistance, Neoplasm; Glioblastoma; Glucosyltransferases; Humans; Paclitaxel; Temozolomide | 2012 |
High incidence of central nervous system involvement in patients with breast cancer treated with epirubicin and docetaxel.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Central Nervous System Neoplasms; Combined Modality Therapy; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Paclitaxel; Taxoids | 2002 |
Polilactofate microspheres for Paclitaxel delivery to central nervous system malignancies.
Topics: Animals; Biocompatible Materials; Blood-Brain Barrier; Cell Line, Tumor; Central Nervous System Neoplasms; Chromatography, High Pressure Liquid; Drug Delivery Systems; Glioma; Inflammation; Male; Microspheres; Paclitaxel; Proportional Hazards Models; Rats; Rats, Inbred F344; Time Factors | 2003 |
Combination of all-trans retinoic acid and paclitaxel-induced differentiation and apoptosis in human glioblastoma U87MG xenografts in nude mice.
Topics: Animals; Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Cell Differentiation; Cell Line, Tumor; Central Nervous System Neoplasms; Cysteine Endopeptidases; Glial Fibrillary Acidic Protein; Glioblastoma; Humans; Inhibitor of Apoptosis Proteins; Mice; Mice, Nude; Mitogen-Activated Protein Kinase Kinases; NF-kappa B; Paclitaxel; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Telomerase; Tretinoin; Ubiquitin-Protein Ligases; Xenograft Model Antitumor Assays | 2008 |
Primary central nervous system recurrence after paclitaxel therapy for epithelial ovarian malignancy.
Topics: Central Nervous System Neoplasms; Cystadenocarcinoma, Serous; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Recurrence; Remission Induction | 1994 |
ICRF-187 rescue in etoposide treatment in vivo. A model targeting high-dose topoisomerase II poisons to CNS tumors.
Topics: Amsacrine; Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Blood-Brain Barrier; Brain Neoplasms; Carcinoma, Ehrlich Tumor; Central Nervous System Neoplasms; DNA Topoisomerases, Type II; Etoposide; Female; Injections, Intraperitoneal; Lethal Dose 50; Leukemia L1210; Male; Mice; Mice, Inbred DBA; Paclitaxel; Razoxane; Structure-Activity Relationship | 1996 |